Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10965227 | Vaccine | 2014 | 4 Pages |
Abstract
This case study provides an example of how Quality by Design (QbD) principles were applied to accelerate process development to manufacture a vaccine candidate at commercial scale. By leveraging an existing manufacturing platform process, a risk assessment was used to differentiate process parameters that could be defined using a combination of scientific and historical manufacturing knowledge from those that merited additional process characterization by experimentation. Select parameters, and their interactions, were evaluated by a Design of Experiment (DoE) series. This systematic approach required less time and fewer resources and resulted in the definition of a reliable and robust manufacturing process that meets regulatory requirements.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Jennifer Haas, Andrew Franklin, Matthew Houser, David Maraldo, Mark Mikola, Roberto Ortiz, Elizabeth Sullivan, José M. Otero,